---
document_datetime: 2025-12-02 05:14:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xtandi.html
document_name: xtandi.html
version: success
processing_time: 0.1377311
conversion_datetime: 2025-12-25 04:23:16.198022
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xtandi

[RSS](/en/individual-human-medicine.xml/66629)

##### Authorised

This medicine is authorised for use in the European Union

enzalutamide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xtandi](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78567)
- [More information on Xtandi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xtandi is a cancer medicine used to treat men with prostate cancer. It can be used:

- together with hormone therapy (treatment to lower production of testosterone) when the cancer is metastatic (has spread to other parts of the body) and is hormone-sensitive (a cancer that depends on a hormone, such as testosterone, to grow);
- for metastatic cancer that is castration-resistant (worsens despite treatment to lower production of testosterone or after surgical removal of the testes) and when either:
    - treatment with docetaxel (a cancer medicine) has not worked or no longer works, or
    - hormone therapy has not worked, and the patient has either no symptoms or mild symptoms and does not yet require chemotherapy (another type of cancer treatment);
- for castration-resistant prostate cancer that is not metastatic (has not yet spread) but is at high risk of doing so;
- on its own or together with hormone therapy for hormone-sensitive prostate cancer that is not metastatic if there are rapidly rising levels of prostate-specific antigen (PSA; a protein made by the prostate gland), indicating that the cancer may have returned, in men who cannot receive salvage radiotherapy (radiation treatment given after the cancer has not responded to other treatments).

The medicine contains the active substance enzalutamide.

Expand section

Collapse section

## How is Xtandi used?

Xtandi can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in treating prostate cancer.

Xtandi is available as capsules and tablets, taken once daily at about the same time each day. The doctor may reduce the dose or interrupt treatment if a patient gets certain side effects.

For more information about using Xtandi, see the package leaflet or contact your doctor or pharmacist.

## How does Xtandi work?

The active substance in Xtandi, enzalutamide, works by blocking the action of the male hormone testosterone and other male hormones known as androgens. Enzalutamide does this by blocking the receptors to which these hormones attach. Because prostate cancer needs testosterone and other male hormones to survive and grow, by blocking the effects of these hormones, enzalutamide slows down the growth of the prostate cancer.

## What benefits of Xtandi have been shown in studies?

**Metastatic prostate cancer**

Xtandi has been compared with placebo (a dummy treatment) in a main study involving 1,199 patients with metastatic, castration-resistant prostate cancer who were previously treated with docetaxel. In this study, Xtandi was more effective than placebo at prolonging patients' lives: on average, patients treated with Xtandi lived for 18 months, compared with 14 months for patients given placebo.

Xtandi has also been compared with placebo in a second main study involving 1,717 patients with metastatic, castration-resistant prostate cancer in whom hormone therapy had failed, but who had no symptoms or mild symptoms and had not previously been treated with chemotherapy. Patients treated with Xtandi lived on average for around 32 months compared with 30 months for patients given placebo. In addition, patients treated with Xtandi lived for longer without their disease showing signs of worsening in a radiographic scan: 20 months compared with 5 months for patients treated with placebo.

A third main study showed that Xtandi was more effective than placebo in 1,150 patients with hormone-sensitive metastatic prostate cancer who either also received hormone therapy to lower testosterone or had their testes surgically removed. The disease got worse more slowly in patients taking Xtandi compared with those given placebo. The average period before the disease got worse in those given placebo was 19 months but the average for those taking Xtandi could not be calculated because the disease had not got worse in many patients during the follow up period.

**Non-metastatic prostate cancer**

Xtandi has been compared with placebo in a study involving 1,401 patients with castration-resistant prostate cancer at high risk of becoming metastatic. Patients treated with Xtandi lived for an average of 37 months without their disease becoming metastatic compared with 15 months on placebo.

Another study involved 1,068  previously treated patients with rapidly rising levels of PSA whose prostate cancer had not spread and was hormone sensitive. In this study patients given Xtandi with leuprolide (a medicine that blocks the production or action of male hormones) or Xtandi on its own lived longer without their disease becoming metastatic compared to those treated with placebo given with leuprolide. Within the study patients' blood levels of PSA were monitored; if their PSA levels were undetectable after 36 weeks, treatment was paused and restarted if their PSA levels began to increase again. After around 61 months, the cancer had spread, or the patient died, in around 13 % of patients given Xtandi with leuprolide (45 out of 355) and around 18% of patients given Xtandi on its own (63 out of 355) compared to around 26% (92 out of 358) of patients given placebo with leuprolide.

## What are the risks associated with Xtandi?

For the full list of side effects and restrictions of Xtandi, see the package leaflet.

The most common side effects with Xtandi (which may affect more than 1 in 10 people) include weakness, tiredness, falls, fractures (broken bones), hot flushes and hypertension (high blood pressure). Other important side effects include ischaemic heart disease (heart disease caused by narrowing or blockage of blood vessels supplying the heart muscle) and seizures.

Xtandi is not for use in women and must not be given to women who are or may become pregnant.

## Why is Xtandi authorised in the EU?

The European Medicines Agency considered that the anticancer effects of Xtandi have been clearly demonstrated and that its benefit in prolonging life of patients with metastatic disease is important for patients. Xtandi has also been shown to delay the development of metastatic disease. Regarding the medicines' safety profile, the side effects with Xtandi are generally mild and can be managed appropriately.

The Agency therefore concluded that Xtandi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Xtandi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xtandi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xtandi are continuously monitored. Side effects reported with Xtandi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xtandi

Xtandi received a marketing authorisation valid throughout the EU on 21 June 2013.

This overview was last updated in 04-2024

Xtandi : EPAR - Medicine overview

Reference Number: EMA/186470/2021

English (EN) (172.39 KB - PDF)

**First published:** 02/07/2013

**Last updated:** 03/06/2024

[View](/en/documents/overview/xtandi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-686)

български (BG) (195.49 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/bg/documents/overview/xtandi-epar-medicine-overview_bg.pdf)

español (ES) (170.76 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/es/documents/overview/xtandi-epar-medicine-overview_es.pdf)

čeština (CS) (194.87 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/cs/documents/overview/xtandi-epar-medicine-overview_cs.pdf)

dansk (DA) (168 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/da/documents/overview/xtandi-epar-medicine-overview_da.pdf)

Deutsch (DE) (173.8 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/de/documents/overview/xtandi-epar-medicine-overview_de.pdf)

eesti keel (ET) (167.26 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/et/documents/overview/xtandi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (195.29 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/el/documents/overview/xtandi-epar-medicine-overview_el.pdf)

français (FR) (171.89 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/fr/documents/overview/xtandi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (192.25 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/hr/documents/overview/xtandi-epar-medicine-overview_hr.pdf)

italiano (IT) (168.02 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/it/documents/overview/xtandi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (199.13 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/lv/documents/overview/xtandi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (193.67 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/lt/documents/overview/xtandi-epar-medicine-overview_lt.pdf)

magyar (HU) (192.74 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/hu/documents/overview/xtandi-epar-medicine-overview_hu.pdf)

Malti (MT) (195.01 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/mt/documents/overview/xtandi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (170.63 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/nl/documents/overview/xtandi-epar-medicine-overview_nl.pdf)

polski (PL) (197.47 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/pl/documents/overview/xtandi-epar-medicine-overview_pl.pdf)

português (PT) (170.69 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/pt/documents/overview/xtandi-epar-medicine-overview_pt.pdf)

română (RO) (189.86 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/ro/documents/overview/xtandi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (195.05 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/sk/documents/overview/xtandi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (191.84 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/sl/documents/overview/xtandi-epar-medicine-overview_sl.pdf)

Suomi (FI) (167.2 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/fi/documents/overview/xtandi-epar-medicine-overview_fi.pdf)

svenska (SV) (168.78 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

03/06/2024

[View](/sv/documents/overview/xtandi-epar-medicine-overview_sv.pdf)

Xtandi : EPAR - Risk management plan

English (EN) (1.3 MB - PDF)

**First published:** 25/01/2019

**Last updated:** 25/04/2024

[View](/en/documents/rmp/xtandi-epar-risk-management-plan_en.pdf)

## Product information

Xtandi : EPAR - Product Information

English (EN) (3.87 MB - PDF)

**First published:** 02/07/2013

**Last updated:** 31/07/2025

[View](/en/documents/product-information/xtandi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-692)

български (BG) (4.26 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/bg/documents/product-information/xtandi-epar-product-information_bg.pdf)

español (ES) (3.8 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/es/documents/product-information/xtandi-epar-product-information_es.pdf)

čeština (CS) (3.51 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/cs/documents/product-information/xtandi-epar-product-information_cs.pdf)

dansk (DA) (3.97 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/da/documents/product-information/xtandi-epar-product-information_da.pdf)

Deutsch (DE) (4.73 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/de/documents/product-information/xtandi-epar-product-information_de.pdf)

eesti keel (ET) (10.48 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/et/documents/product-information/xtandi-epar-product-information_et.pdf)

ελληνικά (EL) (3.65 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/el/documents/product-information/xtandi-epar-product-information_el.pdf)

français (FR) (5.2 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/fr/documents/product-information/xtandi-epar-product-information_fr.pdf)

hrvatski (HR) (5.36 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/hr/documents/product-information/xtandi-epar-product-information_hr.pdf)

íslenska (IS) (4.59 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/is/documents/product-information/xtandi-epar-product-information_is.pdf)

italiano (IT) (4.51 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/it/documents/product-information/xtandi-epar-product-information_it.pdf)

latviešu valoda (LV) (10.39 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/lv/documents/product-information/xtandi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (11.19 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/lt/documents/product-information/xtandi-epar-product-information_lt.pdf)

magyar (HU) (3.57 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/hu/documents/product-information/xtandi-epar-product-information_hu.pdf)

Malti (MT) (3.83 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/mt/documents/product-information/xtandi-epar-product-information_mt.pdf)

Nederlands (NL) (4.97 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/nl/documents/product-information/xtandi-epar-product-information_nl.pdf)

norsk (NO) (14.2 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/no/documents/product-information/xtandi-epar-product-information_no.pdf)

polski (PL) (4.08 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/pl/documents/product-information/xtandi-epar-product-information_pl.pdf)

português (PT) (11.77 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/pt/documents/product-information/xtandi-epar-product-information_pt.pdf)

română (RO) (5.68 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/ro/documents/product-information/xtandi-epar-product-information_ro.pdf)

slovenčina (SK) (10.47 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/sk/documents/product-information/xtandi-epar-product-information_sk.pdf)

slovenščina (SL) (13.42 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/sl/documents/product-information/xtandi-epar-product-information_sl.pdf)

Suomi (FI) (5.27 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/fi/documents/product-information/xtandi-epar-product-information_fi.pdf)

svenska (SV) (4.95 MB - PDF)

**First published:**

02/07/2013

**Last updated:**

31/07/2025

[View](/sv/documents/product-information/xtandi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000289609 31/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xtandi : EPAR - All Authorised presentations

English (EN) (18.07 KB - PDF)

**First published:** 02/07/2013

**Last updated:** 14/03/2018

[View](/en/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-544)

български (BG) (41.17 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/bg/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.49 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/es/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.76 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/cs/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.31 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/da/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.1 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/de/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.4 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/et/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (46.5 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/el/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_el.pdf)

français (FR) (18.1 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/fr/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (26.84 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/hr/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.28 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/is/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.24 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/it/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (39.76 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/lv/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (41.21 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/lt/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.6 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/hu/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.31 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/mt/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.17 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/nl/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.46 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/no/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_no.pdf)

polski (PL) (42.73 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/pl/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.7 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/pt/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.95 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/ro/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.89 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/sk/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (28.2 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/sl/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.33 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/fi/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.3 KB - PDF)

**First published:**

02/07/2013

**Last updated:**

14/03/2018

[View](/sv/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xtandi Active substance enzalutamide International non-proprietary name (INN) or common name enzalutamide Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L02BB04

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Xtandi is indicated for:

- as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy (see section 5.1).
- the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).
- the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
- the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).
- the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

## Authorisation details

EMA product number EMEA/H/C/002639 Marketing authorisation holder

Astellas Pharma Europe B.V.

Sylviusweg 62

Opinion adopted 25/04/2013 Marketing authorisation issued 21/06/2013 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xtandi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (167.49 KB - PDF)

**First published:** 31/07/2025

[View](/en/documents/procedural-steps-after/xtandi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xtandi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (295.46 KB - PDF)

**First published:** 30/10/2014

**Last updated:** 31/07/2025

[View](/en/documents/procedural-steps-after/xtandi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xtandi-H-C-002639-X-0029: EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/432249/2017

English (EN) (4.67 MB - PDF)

**First published:** 02/10/2025

[View](/en/documents/variation-report/xtandi-h-c-002639-x-0029-epar-assessment-report-variation_en.pdf)

Xtandi-H-C-PSUSA-00010095-202308 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/158390/2024

English (EN) (129.93 KB - PDF)

**First published:** 27/06/2024

[View](/en/documents/scientific-conclusion/xtandi-h-c-psusa-00010095-202308-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Xtandi-H-C-002639-II-0063: EPAR - Assessment report - Variation

Reference Number: EMA/CHMP/147735/2024

English (EN) (8.89 MB - PDF)

**First published:** 25/04/2024

[View](/en/documents/variation-report/xtandi-h-c-002639-ii-0063-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xtandi (II-63)

Adopted

Reference Number: EMA/CHMP/87028/2024

English (EN) (159.02 KB - PDF)

**First published:** 22/03/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi-ii-63_en.pdf)

Xtandi-H-C-PSUSA-00010095-202008 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/285965/2021

English (EN) (124.69 KB - PDF)

**First published:** 23/06/2021

[View](/en/documents/scientific-conclusion/xtandi-h-c-psusa-00010095-202008-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Xtandi-H-C-2639-II-0047-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/202601/2021

English (EN) (8.41 MB - PDF)

**First published:** 12/05/2021

[View](/en/documents/variation-report/xtandi-h-c-2639-ii-0047-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xtandi (II-47-G)

Adopted

Reference Number: EMA/CHMP/169064/2021

English (EN) (134.75 KB - PDF)

**First published:** 26/03/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi-ii-47-g_en.pdf)

Xtandi-H-C-2639-II-0039-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/41918/2019

English (EN) (4.13 MB - PDF)

**First published:** 25/01/2019

[View](/en/documents/variation-report/xtandi-h-c-2639-ii-0039-g-epar-assessment-report-variation_en.pdf)

Xtandi-H-C-PSUSA-00010095-201408 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/212233/2015

English (EN) (67.3 KB - PDF)

**First published:** 28/05/2015

**Last updated:** 28/05/2015

[View](/en/documents/scientific-conclusion/xtandi-h-c-psusa-00010095-201408-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xtandi-H-C-2639-II-0008 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/607459/2014

English (EN) (3.76 MB - PDF)

**First published:** 20/01/2015

**Last updated:** 20/01/2015

[View](/en/documents/variation-report/xtandi-h-c-2639-ii-0008-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xtandi

Adopted

Reference Number: EMA/647461/2014

English (EN) (67.78 KB - PDF)

**First published:** 24/10/2014

**Last updated:** 24/10/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi_en.pdf)

## Initial marketing authorisation documents

Xtandi : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/383457/2013

English (EN) (1.17 MB - PDF)

**First published:** 02/07/2013

**Last updated:** 02/07/2013

[View](/en/documents/assessment-report/xtandi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xtandi

Adopted

Reference Number: EMA/CHMP/231975/2013

English (EN) (61.65 KB - PDF)

**First published:** 26/04/2013

**Last updated:** 26/04/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xtandi_en.pdf)

#### News on Xtandi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021) 26/03/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018) 21/09/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 October 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-october-2014) 24/10/2014

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Xtandi : EPAR - Product information - tracked changes

English (EN) (1.26 MB - DOCX)

**First published:** 31/07/2025

[View](/en/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-416)

български (BG) (1.54 MB - DOCX)

**First published:**

31/07/2025

[View](/bg/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_bg.docx)

español (ES) (1.13 MB - DOCX)

**First published:**

31/07/2025

[View](/es/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_es.docx)

čeština (CS) (1.92 MB - DOCX)

**First published:**

31/07/2025

[View](/cs/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (830.77 KB - DOCX)

**First published:**

31/07/2025

[View](/da/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (908.13 KB - DOCX)

**First published:**

31/07/2025

[View](/de/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (1.02 MB - DOCX)

**First published:**

31/07/2025

[View](/et/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (835.52 KB - DOCX)

**First published:**

31/07/2025

[View](/el/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_el.docx)

français (FR) (1.31 MB - DOCX)

**First published:**

31/07/2025

[View](/fr/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (1.66 MB - DOCX)

**First published:**

31/07/2025

[View](/hr/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (1.4 MB - DOCX)

**First published:**

31/07/2025

[View](/is/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_is.docx)

italiano (IT) (1.44 MB - DOCX)

**First published:**

31/07/2025

[View](/it/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (937.79 KB - DOCX)

**First published:**

31/07/2025

[View](/lv/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (921.11 KB - DOCX)

**First published:**

31/07/2025

[View](/lt/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (1.23 MB - DOCX)

**First published:**

31/07/2025

[View](/hu/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (1.75 MB - DOCX)

**First published:**

31/07/2025

[View](/mt/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (2.67 MB - DOCX)

**First published:**

31/07/2025

[View](/nl/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (1.16 MB - DOCX)

**First published:**

31/07/2025

[View](/no/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_no.docx)

polski (PL) (997.21 KB - DOCX)

**First published:**

31/07/2025

[View](/pl/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_pl.docx)

português (PT) (1.31 MB - DOCX)

**First published:**

31/07/2025

[View](/pt/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_pt.docx)

română (RO) (1.99 MB - DOCX)

**First published:**

31/07/2025

[View](/ro/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (1.15 MB - DOCX)

**First published:**

31/07/2025

[View](/sk/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (1.58 MB - DOCX)

**First published:**

31/07/2025

[View](/sl/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (1.39 MB - DOCX)

**First published:**

31/07/2025

[View](/fi/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (2.06 MB - DOCX)

**First published:**

31/07/2025

[View](/sv/documents/product-information-tracked-changes/xtandi-epar-product-information-tracked-changes_sv.docx)

#### More information on Xtandi

- [Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000776)
- [A multicentre, non-interventional, cohort analysis describing the patients' experience focusing on safety events among metastatic hormone-sensitive prostate cancer patients treated with Androgen Receptor Pathway Inhibitors (ARPIs) followed through a Telemonitoring tool funded by the French national healthcare insurance complemented with a chart review (ESPERANTO) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000759)
- [An International, Multicenter, Prospective Non-Interventional Study of Real-World Treatment Outcomes in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) treated with Talazoparib and Enzalutamide (TALENZA) - post-authorisation study](https://catalogues.ema.europa.eu/study/106720)
- [A Multicenter, Single-arm, Open-label, Post-marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure - post-authorisation study](https://catalogues.ema.europa.eu/study/32806)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/11/2025

## Share this page

[Back to top](#main-content)